LPA and venous thromboembolism: Reductions of Lp(a) by alirocumab were associated with a reduction in primary peripheral arterial events, venous thromboembolism, and major cardiovascular events, independent of LDL-C reduction, supporting the concept that circulating Lp(a) is a modifiable CVD risk factor.